* Taro Pharmaceutical Industries Ltd TARO.N TARO.K is
expected to show a rise in quarterly revenue when it reports
results on July 27.
* The Haifa, Israel-based company is expected to report a
16.7% increase in revenue to $137.229 million from $117.63
million a year ago, according to the estimate from one analyst,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for Taro Pharmaceutical
Industries Ltd is for earnings of 84 cents per share. For the
same quarter last year, the company reported a loss of $11.37
per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for Taro
Pharmaceutical Industries Ltd is $80, about 12% above its last
closing price of $70.44.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINE REFINITIV ACTUAL BEAT, SURPRI
ENDING SMARTESTIM IBES MET, SE %
ATE® ESTIMATE MISSED
Mar. 31 2021 0.92 0.92 -0.78 Missed -184.8
Dec. 31 2020 1.01 1.01 0.86 Missed -14.9
Sep. 30 2020 0.77 0.77 1.18 Beat 53.2
Jun. 30 2020 1.16 1.16 -11.37 Missed -1,080
.2
Mar. 1.53 1.53 1.42 Missed -7.2
31 2020
Dec. 31 2019 1.54 1.54 1.76 Beat 14.3
Sep. 30 2019 1.72 1.72 1.46 Missed -15.1
Jun. 30 2019 1.96 1.96 1.72 Missed -12.2
This summary was machine generated July 23 at 23:50 GMT. All
figures in US dollars unless otherwise stated